The Role of NOD Mice in Type 1 Diabetes Research: Lessons from the Past and Recommendations for the Future
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
For more than 35 years, the NOD mouse has been the primary animal model for studying autoimmune diabetes. During this time, striking similarities to the human disease have been uncovered. In both species, unusual polymorphisms in a major histocompatibility complex (MHC) class II molecule confer the most disease risk, disease is caused by perturbations by the same genes or different genes in the same biological pathways and that diabetes onset is preceded by the presence of circulating autoreactive T cells and autoantibodies that recognize many of the same islet antigens. However, the relevance of the NOD model is frequently challenged due to past failures translating therapies from NOD mice to humans and because the appearance of insulitis in mice and some patients is different. Nevertheless, the NOD mouse remains a pillar of autoimmune diabetes research for its usefulness as a preclinical model and because it provides access to invasive procedures as well as tissues that are rarely procured from patients or controls. The current article is focused on approaches to improve the NOD mouse by addressing reasons why immune therapies have failed to translate from mice to humans. We also propose new strategies for mixing and editing the NOD genome to improve the model in ways that will better advance our understanding of human diabetes. As proof of concept, we report that diabetes is completely suppressed in a knock-in NOD strain with a serine to aspartic acid substitution at position 57 in the MHC class II Aβ. This supports that similar non-aspartic acid substitutions at residue 57 of variants of the human class II HLA-DQβ homolog confer diabetes risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity
Markle, J. G. M., Frank, D. N., Mortin-Toth, S., Robertson, C. E., Feazel, L. M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K. D., Macpherson, A. J., & Danska, J. S. (2013) · Science · doi:10.1126/science.1233521 · Cited by 2,025
Innate immunity and intestinal microbiota in the development of Type 1 diabetes
Wen, L., Ley, R. E., Volchkov, P. Y., Stranges, P. B., Avanesyan, L., Stonebraker, A. C., Hu, C., Wong, F. S., Szot, G. L., Bluestone, J. A., et al. (2008) · Nature · doi:10.1038/nature07336 · Cited by 1,921
The Type 1 Diabetes Genetics Consortium, Barrett, J. C., Clayton, D. G., Concannon, P., Akolkar, B., Cooper, J. D., Erlich, H. A., Julier, C., Morahan, G., Nerup, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.381 · Cited by 1,746
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
Finland, G. O. T. 1. D. I., Todd, J. A., the Wellcome Trust Case Control Consortium, Walker, N. M., Cooper, J. D., Smyth, D. J., Downes, K., Plagnol, V., Bailey, R., Nejentsev, S., et al. (2007) · Nature Genetics · doi:10.1038/ng2068 · Cited by 1,456 · cited 1×
“Furthermore, the causative gene has yet to be identified for the chromosome 4q27 region containing IL2 and IL21 that is linked with T1D susceptibility (81).”
BackgroundVariation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans
Vatanen, T., Kostic, A. D., d’Hennezel, E., Siljander, H., Franzosa, E. A., Yassour, M., Kolde, R., Vlamakis, H., Arthur, T. D., Hämäläinen, A.-M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.007 · Cited by 1,289
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases
Geurts, A. M., Cost, G. J., Freyvert, Y., Zeitler, B., Miller, J. C., Choi, V. M., Jenkins, S. S., Wood, A., Cui, X., Meng, X., et al. (2009) · Science · doi:10.1126/science.1172447 · Cited by 934
Effects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Effects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Näntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Early prediction of autoimmune (type 1) diabetes.
Regnell, S. E., & Lernmark, Å. (2017) · Diabetologia · doi:10.1007/s00125-017-4308-1 · Cited by 195 · cited 1×
“However, in the NOD mouse, the initiating antigen appears to be insulin (1), whereas in human T1D it is thought to result from several initiating antigens (5, 6).”
BackgroundSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“Preclinical studies using these modalities demonstrated an ability to reverse T1D in 39% of NOD females after onset (25).”
Haller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Rosenthal, S. M., Shuster, J. J., Zou, B., Brusko, T. M., Hulme, M. A., Wasserfall, C. H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78492 · Cited by 167
Self-citationElliott, J. F., Liu, J., Yuan, Z.-N., Bautista-Lopez, N., Wallbank, S. L., Suzuki, K., Rayner, D., Nation, P., Robertson, M. A., Liu, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235552100 · Cited by 80
Haller, M. J., Gitelman, S. E., Gottlieb, P. A., Michels, A. W., Perry, D. J., Schultz, A. R., Hulme, M. A., Shuster, J. J., Zou, B., Wasserfall, C. H., et al. (2016) · Diabetes · doi:10.2337/db16-0823 · Cited by 70
Self-citationWinkler, C., Krumsiek, J., Lempainen, J., Achenbach, P., Grallert, H., Giannopoulou, E., Bunk, M., Theis, F. J., Bonifacio, E., & Ziegler, A.-G. (2012) · Genes & Immunity · doi:10.1038/gene.2012.36 · Cited by 68 · cited 6×
“that genotyped 12 non-HLA susceptibility genes (ERBB3, PTPN2, IFIH1, PTPN22, CLEC16A, CD25, CTLA4, SH2B3, IL2, IL18RAP, IL10, and COBL) in high-risk HLA positive children of parents with T1D that were prospectively followed from birth to the development of autoantibodies and disease (19).”
BackgroundInfluentialEvaluating Preclinical Efficacy
Atkinson, M. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002757 · Cited by 39
Cited by
Neutrophils in chronic inflammatory diseases
Herrero-Cervera, A., Soehnlein, O., & Kenne, E. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00832-3 · Cited by 695
Probiotics and prebiotics for the amelioration of type 1 diabetes: Present and future perspectives
Mishra, S., Wang, S., Nagpal, R., Miller, B., Singh, R., Taraphder, S., & Yadav, H. (2019) · Microorganisms · doi:10.3390/microorganisms7030067 · Cited by 131
“Some of the most common animal models used to study the effect of probiotics, prebiotics and drugs on T1D are NOD mice [61], Streptozotocin (STZ)-induced T1D rats and mice [62,63], Alloxan-induced T1D Swiss Webster mice [64], BBDR rats [65,66], and Bio-Breeding Diabetic Pathogen (BBDP) rats [65,66].”
BackgroundAutoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3
Grebinoski, S., Zhang, Q., Cillo, A. R., Manne, S., Xiao, H., Brunazzi, E. A., Tabib, T., Cardello, C., Lian, C. G., Murphy, G. F., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01210-5 · Cited by 107
Grattoni, A., Korbutt, G., Tomei, A. A., García, A. J., Pepper, A. R., Stabler, C., Brehm, M., Papas, K., Citro, A., Shirwan, H., et al. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01029-0 · Cited by 92
Metadata
- Authors
- Chen, Y.-G., Mathews, C. E., & Driver, J. P.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2018-02-23
- Volume
- 9
- Pages
- 51-51
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2792081113
- Cited by
- 134
- References
- 21
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.